Stay updated with breaking news from Rev Nephrol. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Issuer: SphingoTec GmbH / Key word(s): Research Update/Study results ADQI Group Recognizes PenKid as Relevant Functional Biomarker for Sepsis-Associated Acute Kidney Injury 04.04.2023 / 10:00 CET/CEST The issuer is solely responsible for the content of this announcement. The Acute Disease Qualit...
Issuer: SphingoTec GmbH / Key word(s): Research Update/Study results ADQI Group Recognizes PenKid as Relevant Functional Biomarker for Sepsis-Associated Acute Kidney Injury 04.04.2023
The non-physician community health-care provider-led intensive blood pressure intervention is effective in reducing cardiovascular disease and death.
Type 2 diabetes accounts for nearly 90% of the approximately 537 million cases of diabetes worldwide. The number affected is increasing rapidly with alarming trends in children and young adults (up to age 40 years). Early detection and proactive management are crucial for prevention and mitigation of microvascular and macrovascular complications and mortality burden. Access to novel therapies improves person-centred outcomes beyond glycaemic control. Precision medicine, including multiomics and pharmacogenomics, hold promise to enhance understanding of disease heterogeneity, leading to targete...
NICE Recommends Astellas’ EVRENZO▼™ (roxadustat) For Adults With Symptomatic Anaemia Associated With Chronic Kidney Disease EVRENZOTM (roxadustat) is the first hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor to be recommended by NICE1Over 75,000 adults in England and Wales living with...